Bayer AG wants attorneys to stop advertising for new clients to sue over Roundup cancer claims, according to U.S. News & World Report.
The company acquired Roundup maker Monsanto for $63 billion in 2018. Shortly afterward, the company was hit with three multi-million-dollar verdicts in back-to-back trials alleging the company knew that the active ingredient glyphosate in Roundup weed killer could cause non-Hodgkin’s lymphoma, but failed to warn regulators or consumers. The latest trial was paused last week in the 11th hour as Bayer works with a mediator to negotiate a global settlement for some 42,000 lawsuits.
The mediator, Ken Feinberg, told Bloomberg last month that the number of lawsuits plaguing the Germany-based company could be as high as 75,000 to 85,000, and “Maybe more.” But a spokesperson for Bayer said that number is purely speculative and that the real number “remains significantly below 50,000.”
Weighed down by the growing number of lawsuits, Bayer wants to strike a deal with plaintiffs’ attorneys to stop advertising for new clients, a source familiar with the matter told U.S. News. Bayer reportedly blames the spike in Roundup lawsuits on lawyers’ ads.
In related news, German newspaper Handelsblatter reported that Bayer was considering halting retail sales of Roundup but still sell it to farmers since the majority of plaintiffs suing the company over cancer claims are private users. Bayer didn’t comment.
Since it acquired Monsanto, Bayer has held firm that glyphosate is safe despite the World Health Organization’s International Agency for Research on Cancer in 2015 classifying the chemical as a probable carcinogen.
Beasley Allen lawyers are currently representing clients who have been exposed to Roundup and developed non-Hodgkin’s lymphoma. For more information, contact a member of our Roundup Litigation Team: John Tomlinson (who heads up the team), Michael Dunphy, Danielle Ingram or Rhon Jones, all lawyers in our Toxic Torts Section.